

1 Hemsley *et al.* – Supplementary Information

3 Persister transcriptome.

4 To characterise the physiological state of drug-tolerant cells, the transcriptome of
5 ceftazidime-survivors was sequenced. Samples were obtained by isolating RNA from
6 stationary phase cells which had been treated with 100 x MIC ceftazidime for 24 hrs
7 at 37 °C. The transcriptome was compared to the transcriptome of bacteria which
8 had been grown in LB broth to mid-log phase ($OD_{600nm} = 0.5-0.6$; abbreviated as
9 LBML) or to stationary phase ($OD_{600nm} = 4.5-5.5$; abbreviated as LBS). The
10 reproducibility between biological replicates was assessed by linear regression
11 analyses, where the coefficients of determination (R^2) ranged between 0.9905 and
12 0.9997 between biological replicates (Fig. S1A-C). The average number of reads per
13 gene was 1,934 for mid-log phase samples (maximum of 292,702 reads). In
14 contrast, the average number of reads per gene was 1,069 for ceftazidime-survivors,
15 with a maximum of 191,687, which indicates that the overall gene expression level is
16 reduced in ceftazidime-survivors compared to actively growing cells. In LBS
17 samples, the average and maximum number of reads per gene were 1,927 and
18 1,093,163, respectively. The maximum number of reads dropped to 354,873, when
19 BTH_I1628, encoding a small RNA with similarity to tmRNA, was excluded.

20
21 According to the transcriptome data, genes involved in nitrogen metabolism such as
22 the nitric oxide reductase and the nitrate reductase (NarGHI) of the large
23 chromosome, including the activators NarL and NarX (encoding a two component
24 system), are induced in persister cells compared to both mid-log and stationary
25 phase cells (Fig. S1H). *B. pseudomallei* (1) and *B. thailandensis* (2) are able to grow

26 anaerobically using nitrate as terminal electron acceptor. Induction of the nitrate
27 reductases in persister cell samples is surprising as no nitrate was present during
28 growth and challenge with antibiotics. Genes of the arginine deimination (ADI)
29 pathway are the most highly up-regulated genes in persisters. The first enzyme of
30 the ADI pathway, the arginine deiminase, converts L-arginine to L-citrulline and
31 ammonia (Fig. S1H). Citrulline is degraded further forming ATP, CO₂, and L-
32 ornithine (3). Hence, the ADI pathway provides energy in the absence of oxygen
33 and also feeds into carbon and nitrogen metabolism. In addition, it has been
34 suggested that the pathway can also protect some bacteria from acidic conditions,
35 by the production of ammonia (4). Indeed, *Burkholderia pseudomallei* mutants in the
36 ADI pathway have recently been described as exhibiting decreased survival rates at
37 low pH (5). The same authors described increased expression of the *arcA* and *arcC*
38 genes in certain colony morphotypes, but could not demonstrate a role for the ADI
39 pathway in survival in macrophages. *B. thailandensis* does not form colony
40 morphology variants to the same extent as *B. pseudomallei*. Nevertheless, the
41 results substantiate a fitness advantage of cells with an active ADI pathway. The
42 role of the arginine deimination pathway in virulence in animal models and chronic
43 disease remains to be elucidated.

44

45 The promoter prediction tool Bprom (freely available at the Softberry homepage)
46 predicted binding sites of the transcriptional regulator Fnr in vicinity of some
47 promoters within the denitrification pathway and the ADI pathway operons (see Fig.
48 S1H). Fnr has been extensively studied in *E. coli*, where it mediates the transition
49 from aerobic to anaerobic growth (6). *B. thailandensis* strain E264 possesses three
50 proteins with homology to the *E. coli* Fnr protein, BTH_II0035, BTH_II0460, and

51 BTH_II1244. The first two proteins were expressed at slightly higher levels in
52 persisters compared to LBML samples only. However, Fnr activation in response to
53 hypoxia is achieved through changes in the redox state of an internal iron-sulfur
54 cluster (7), and not through transcriptional activation. The role of Fnr in the
55 anaerobic adaptation in *Burkholderia* remains to be established.

56

57 The download link for the persister datasets is:

58 http://osslab.ex.ac.uk/downloads/RNAseq-data_Hemsley_et_al.xls

59

60 **Comparison with the transcriptomes of *M. tuberculosis* and *E. coli* persister**
61 **cells.**

62 In order to identify commonalities between persisters cells from different organisms,
63 the *B. thailandensis* transcriptome described here was compared to reported
64 microarray data from *M. tuberculosis* persisters (6) and *E. coli* persisters (7, 8). This
65 identified 16 genes that were commonly induced in drug-tolerant *B. thailandensis*
66 and in *M. tuberculosis* persister cells (Fig S2). Seven of the genes encode predicted
67 inner membrane proteins, and one conserved hypothetical protein of *M.*
68 *tuberculosis*, Rv0140, has been found in culture filtrates (9). Two transcriptional
69 regulators are among the list of commonly induced genes, and a variety of stress-
70 related gene product such as heat-shock proteins and a universal stress protein.
71 The latter, however, was only found to be up-regulated in persisters compared to
72 mid-log phase cells but not to stationary-phase cells, thereby highlighting the effect
73 of the reference sample in such transcriptome analyses. Only two of the commonly
74 induced genes, the heat shock protein *htpX* and a member of the Hsp20 family,
75 have also been described as being expressed in *E. coli* persisters, thereby

76 indicating a possible role of the heat shock response in persister cell formation
77 across various organisms. Interestingly, over-expression of *hspX* in *M. tuberculosis*
78 has been shown to result in reduced growth rates both *in vivo* and *in vitro* (10),
79 thereby adding evidence to a possible role of HspX in maintaining a slow-growing
80 phenotype.

81

82 **Role of the heat-shock response.**

83 We could not confirm activation of the heat-shock response in drug-tolerant cells (Fig
84 S3). The heat shock sigma-factor *rpoH* was expressed at 3-times higher levels in
85 drug-tolerant cells compared to both mid-log and stationary phase cells. The heat
86 shock proteins HtpX (BTH_I0131) and two members of the Hsp20 family
87 (BTH_I2809 and BTH_I2810), as well as the chaperone protein DnaK (BTH_I1308)
88 were also induced in persisters. We also found elevated expression levels of some
89 ATP-dependent proteases such as Lon and Clp proteases in drug-tolerant cells
90 compared to mid-log phase cells, but not compared to stationary phase cells. Only
91 one copy of the Zn-dependent oligopeptidase PrlC (BTH_I1860) was 2.4-fold
92 induced in drug-tolerant cells. Finally, BTH_I2241 encoding the FtsH protease
93 activity modulator HflK, and its downstream gene were up-regulated in drug-tolerant
94 cells compared to stationary phase cells. FtsH has been shown to regulate RpoH
95 levels and is important for maintaining membrane integrity (11). In *M. tuberculosis*,
96 FtsH is involved in resistance to reactive oxygen species and regulates the cell
97 division protein FtsZ (12) and in *C. crescentus*, *ftsH* mutants exhibit increased
98 sensitivity to antibiotics and form filaments (13).

99

100 **Contribution of β -lactamases and multidrug efflux pumps.**

101 According to our RNAseq data, four putative β -lactamases, BTH__1908,
102 BTH_I10372-0373, and BTH_I11450, were induced in drug-tolerant cells (Fig S4A).
103 The latter represents a homologue of PenA, a secreted β -lactamase that increases
104 resistance to β -lactam antibiotics when over-expressed in *B. pseudomallei* (14).
105 However, we found that the remaining ceftazidime concentration after 24 hrs
106 incubation at 37°C in the absence and presence of bacteria was approx. 95% of the
107 initial concentration (i.e. 95x MIC) in both cases, thereby ruling out loss of activity by
108 natural or bacterial degradation (see Fig S4 B&C). The expression of several
109 multidrug-efflux pumps, including the BpeAB-OprB systems and the AmrAB-OprA
110 system, was induced in persister (Fig S4A).

111

112 **Comparison of the Two, Three and Four State Stochastic Switching models.**

113 This section combines arguments, data and simulations to describe the relative
114 effectiveness of the two, three and four state models in accounting for the data
115 presented in the main text. In addition to changing the atmospheric oxygen levels,
116 we also determined the number of persister cells in response to differences in the
117 volume of the culture. Because these cultures were unshaken, and considering the
118 diffusion of oxygen into water and broth was governed similarly, we were able to
119 predict the oxygen levels in the broth in response to differences in culture volume
120 (Fig S5A). Figures 1B and S5B demonstrate that the number of bacterial survivors
121 under 24 hrs of ceftazidime treatment varied over about five orders of magnitude
122 between conditions of high and low oxygen supply. However, in both experiments
123 where oxygen levels were altered, either being explicitly controlled or when it was
124 varied indirectly by changing the assay volume, the frequency of survivors revealed
125 after 24 hrs of ciprofloxacin treatment stayed consistently at around 10^{-4} .

126

127 **Two-State Model.** The two-state model (see Fig. S6A) proposes that there are two
128 phenotypically distinct states, one with (p) and one without (n) antibiotic tolerance.
129 Cells are assumed to stochastically switch between these states at rates a and b . As
130 seen in Figure 1C, kill curves for both ciprofloxacin and ceftazidime exposure
131 showed biphasic killing. These persister subpopulations however plateau at
132 significantly different levels. Under ciprofloxacin treatment, the slope of the second
133 phase (corresponds to the death rate k_p) was not very steep. This, combined with the
134 consistency in survivor numbers to ciprofloxacin treatment after 24h under different
135 oxygen regimes, strongly suggests that the switching rates (a and b) are not
136 changing if p is to represent the ciprofloxacin-tolerant persister state. However, the
137 very opposite is suggested under exposure to ceftazidime, where the killing efficacy
138 changes many orders of magnitude with oxygen levels (Fig. S5B). The largest
139 change that needs to be accounted for from the experiments is the difference
140 observed by changing the assay volume from either 0.25 ml or 0.5 ml to 1 ml or 2 ml.

141

142 Using the analytical solution for the two-state switching model derived by Balaban *et*
143 *al.* (15), we tested extensive regions of the parameter space summarised in Table
144 S2 to match the killing data for ceftazidime and ciprofloxacin in various regimes.
145 While some of these ranges appeared to overlap, a closer examination revealed that
146 the parameter ranges must vary in order to account for the three separate killing
147 regimes as illustrated in Figure S7 for the switching rates a and b when considered
148 in tandem. In particular, comparing the ceftazidime treatment regimes revealed that
149 the switching rates between the two states must change in order to account for the
150 data. This is further illustrated in Figure S8, which plots two cases in which it is

151 assumed that $k_p = 0$ so that the other three parameters can be plotted. Very clear
152 parameter changes are indicated by the separation of the parameter sets between
153 high and low survivor numbers under ceftazidime treatment at different volumes.
154 Thus the consistency of survivors from the ciprofloxacin treatment suggests there
155 needs to be at least one additional subpopulation and hence a phenotypic state in
156 the model. We conclude that at least a three-state stochastic switching model is
157 required to explain the data.

158

159 **Three-State Model.** The most general three-state stochastic switching model is
160 presented in Figure S4B, with presumably two persister states p_1 and p_2 in addition
161 to the fully susceptible n state. For convenience, we chose the p_2 persisters to be
162 those tolerant to ciprofloxacin. Kill curve data and the oxygen controlled assays
163 (whether through volume or direct oxygen control) indicate that the killing of this
164 subpopulation is seemingly independent of the oxygen content. This suggests that,
165 independent of the oxygen concentration, this subpopulation should only be reduced
166 to about 10^{-4} after 24 hrs of ciprofloxacin treatment. We know that the number of
167 ceftazidime persisters is dependent on the oxygen level available. Thus the rates a
168 and b are likely to vary under different oxygen conditions as the population size of
169 anaerobic cells (p_1) needs to be mediated by oxygen. Therefore, we conclude that
170 the switching rates in Figure S4B have the property that $f=d$ and $e=c$ (giving us the
171 new model in Fig. S6C). Otherwise the consistency in the number of cells surviving
172 ciprofloxacin treatment would also be oxygen dependent. To confirm this argument,
173 parameter regimes of the ODE model presented in Figure S6C were extensively
174 searched for solutions that could fulfil both the variability in ceftazidime-killing under
175 different oxygen conditions and the consistent ciprofloxacin-killing. In each search,

176 the rates c and d were fixed to the best possible fit to the kill curve of ciprofloxacin at
177 a 1 ml assay volume (see Fig. S5B). The other rates were then seeded over varying
178 ranges and random walks were conducted of up to 1,000 steps searching for
179 solutions which would fulfil the requisite high and low survivor numbers under
180 ceftazidime-killing at various assay volumes. In no cases was a parameter set found
181 which could even approach the total low number of survivors that a 0.5 ml assay
182 volume would find (between 7.6×10^{-7} and 1.7×10^{-6} after 24 hrs ceftazidime). This is
183 not surprising as the necessarily non-zero rates of c and d cause a buffering effect.
184 These simulations did assume that the ciprofloxacin-tolerant persisters possess a
185 similar tolerance to the ceftazidime drug as the anaerobic cells. The model could
186 account for the data if it is assumed that the drug tolerance of the ciprofloxacin-
187 tolerant cells with respect to ceftazidime exposure is oxygen dependent. However
188 the model then loses any real explanatory or predictive power and becomes a purely
189 fitting based exercise with no indication of how the behaviour may or may not
190 change under different conditions.

191

192 Thus while the three-state model can capture some of the features of the
193 experiments, it is unable to simultaneously capture all of the possible killing under
194 different conditions while including all the features which have been indicated to be
195 present from the experiments. The most evident being the independence of the
196 number of ciprofloxacin survivors from oxygen conditions.

197

198 **Four State Model.** The four-state model presented in Figure 3A proposes the
199 incorporation of two stochastic switches into each cell. The switching rates between
200 ciprofloxacin non-tolerance (n or n) and tolerance (p or p) is assumed to be

201 independent of oxygen. Thus, independent of the oxygen content of the
202 environment, the number of ciprofloxacin persisters which survive treatment is
203 consistent. However the other switch between a presumably aerobic or anaerobic
204 metabolism is assumed to depend on the oxygen level of the environment. This new
205 model can now fit all the data we have presented as indicated in Figure 3B. Indeed,
206 in that example, only the switch out rate b from the anaerobic state needed to be
207 modified to account for the different killing profiles observed under different levels of
208 oxygen.

209

210 **Burkholderia pseudomallei anaerobic nitrate respiration (denitrification)**

211 *B. thailandensis* and *B. pseudomallei* can grow anaerobically in the presence of
212 nitrate (1, 2), using the denitrification pathway. Denitrification requires a series of
213 reductase enzyme; nitrate reductase (NarGHI), nitrite reductase (Nir), nitric oxide
214 reductase (Nor) and nitrous oxide (Nos), to sequentially reduce nitrate to dinitrogen
215 gas (16). The first step in the denitrification (also referred to as anaerobic nitrate
216 respiration pathway) utilises a membrane-bound nitrate reductase (NarGHI),
217 required for the reduction of nitrate to nitrite and generation of a PMF (17). *B.*
218 *pseudomallei* encodes two membrane-bound nitrate reductase enzymes *narGHJI*
219 (BPSL2309-2312), predicted to be the main Nar required for anaerobic respiration
220 and *narZYWV* (BPSS1156-1159) displaying homology to the cryptic NarZYWV found
221 in *E. coli* and *Salmonella*. Both of these gene clusters share high sequence identity
222 (90-99%) with respective homologous gene clusters in *B. thailandensis* BTH_I1851-
223 BTH_I1854 (*narGHJI*) and BTH_II1249-1252 (*narZYWV*). The BTH_I11851-1854
224 gene cluster was shown to be upregulated in persister cells, whereas the second
225 nitrate reductase BTH_II1249-1252 (*narZYWV*) was downregulated.

226

227 In order to determine the role of anaerobic respiration in persister cell formation a
228 *narG* (BPSL2309) deletion mutant was constructed using the pDM4 suicide vector.
229 The deletion of *narG* was confirmed using two sets of PCR, one using primers
230 binding to a 300 bp internal region of the gene (not shown) and one using primers
231 binding 300 bp up and downstream of the target gene, generating a 600 bp product
232 in the mutant and a much larger product (approximately 3,500 bp) in the wild-type.
233 No wild-type PCR product was detected under the cycle conditions used in this study
234 (Fig. S9A). Deletion of *narG* ($\Delta narG$) prevented growth of *B. pseudomallei*
235 anaerobically in the presence of nitrate, but did not affect aerobic growth in either M9
236 minimal media or L-broth (Fig. S9 B – C and E). In order to confirm the $\Delta narG$
237 mutant was deficient in Nar activity a Griess reaction (Promega) was performed on
238 aerobically grown wild-type and mutant *B. pseudomallei* cultures (grown in M9
239 minimal media supplemented with 20 mM sodium succinate and 20 mM sodium
240 nitrate). The concentration of nitrite produced during aerobic growth and therefore
241 relative Nar activity was determined using the Griess reaction and a nitrite standard
242 curve. Only the wild-type accumulated significant amounts of nitrite after 8 hours of
243 growth under aerobic conditions (Fig. S9D). After 24 hours of aerobic growth in the
244 presence of nitrate wild-type *B. pseudomallei* accumulated around 256 μ M nitrite
245 whereas the $\Delta narG$ mutant accumulated only 7 μ M nitrite. This indicated that NarGHI
246 may be active under both aerobic and anaerobic conditions. The results from these
247 experiments indicate BPSL2309-2312 (*narGHJI*) encodes the main nitrate reductase
248 in *B. pseudomallei* required for anaerobic respiration and nitrate reductase activity.

249

250 **Regrowth rates and phenotypes on plates**

251 We observed differences in the re-growth rates between ceftazidime and
252 ciprofloxacin-survivors (see Fig. S10), with the former forming colonies of uniform
253 size on LB agar plates after 24 hrs incubation at 37 °C, whereas ciprofloxacin
254 survivors requiring 48 hrs incubation before visible colonies of variable sizes are
255 formed on plate. This suggests that ceftazidime-survivors seem to be able to rapidly
256 resume growth, which might be the result of the maintained metabolic activity. The
257 differences in the re-growth rates between ciprofloxacin- and ceftazidime survivors
258 also indicate that they might have reached different dormancy levels. It has
259 previously been suggested that dormancy levels can be divided into three stages,
260 which coincide with arrests of growth, DNA replication, and protein synthesis,
261 respectively, and that these levels correlate with resistance to different classes of
262 antibiotics i.e. β -lactams, quinolones, and aminoglycosides (18).

263

264 SUPPLEMENTARY METHODS

265

266 **Anaerobic growth experiments.** *B. pseudomallei* anaerobic growth studies were
267 conducted using the BD GasPak EZ incubation system and two Gas Pak EZ
268 anaerobic container system sachets with indicator. M9 minimal media supplemented
269 with nitrate was used for the anaerobic growth studies and Griess reaction. M9
270 minimal media was supplemented with or without sodium nitrate (NaNO_3^-) or sodium
271 nitrite (NaNO_2^-) (0-20 mM) and 20 mM succinate as a carbon and electron source.
272 M9 media contained 2 mM MgSO_4 , 0.1 mM CaCl_2 , 20 % M9 salts (5 x stock solution;
273 85.5 g/l-1 Na_2HPO_4 , 15 g/l-1 KH_2PO_4 , 2.5 g/l-1 NaCl , 5 g/l-1 NH_4Cl). Wild-type *B.*
274 *pseudomallei* and $\Delta narG$ overnight cultures were standardised and inoculated into
275 M9 minimal media supplemented with or without 20 mM sodium nitrate. CFU counts

276 were performed by spot plating serial dilutions onto LB agar plates incubated
277 aerobically at 37 °C.

278

279 **Nitrate reductase activity assay.** The concentration of nitrite produced throughout
280 aerobic growth in M9 minimal media was measured using the Griess Reagent
281 system (Promega). 1 mL samples were taken throughout the growth cycle and
282 frozen at -80 °C prior to performing the Griess reaction. A nitrite standard curve was
283 generated for each experiment to ensure accurate estimations of nitrite
284 concentration in the sample medium. Three independent biological replicates were
285 used, each with three technical replicates.

286


287

288

289

290

291

292 **SUPPLEMENTARY FIGURES**

293

294 **Fig. S1. RNAseq data. (A-C)** Reproducibility between biological replicates.

295 Representative scatter plots of read count data of two biological replicates of LBML

296 samples (A), LBS samples (B), and ceftazidime-survivors (C), respectively. **(D-F)**

297 Comparison of different conditions. Scatter plots of average read counts of LBS vs.

298 LBML samples (D), ceftazidime-survivors vs. LBML samples (E), and ceftazidime-

299 survivors vs. LBS samples (F), respectively. In A-F, coefficients of determination (R^2)

300 were calculated based on linear regression analyses. **(G)** Numbers within the Venn
301 diagram represent genes that are specifically expressed under one or two
302 conditions, or which are equally expressed under all three conditions (center of
303 diagram). **(H)** Pathway analysis of the 306 genes that were specifically expressed in
304 ceftazidime survivors revealed that all genes within the nitrate respiration
305 (denitrification) pathway and the arginine deimination pathway were significantly
306 upregulated in persisters compared to LBML and LBS samples. These pathways are
307 controlled by various external stimuli through transcriptional regulators.

308

309

Protein function	Bt-P/ML	Bt-P/S	TB-P	EC-P	Bt ID	TB ID	Ec ID	Localisation	
Heat shock protein HtpX	Orange	Green	Green	Green	BTH_I0131	Rv0563	<i>htpX</i>	IM	
Sulphate permease family of anion transporters	Orange	Green	Green	Green	BTH_I1051	Rv1707	<i>ychM</i>	IM	
Peptidase, M50 family / conserved transmembrane protein	Orange	Green	Green	Green	BTH_I1903	Rv2625c	<i>rseP*</i>	IM	
Transcriptional regulator, MerR family	Orange	Green	Green	Green	BTH_I2208	Rv3334	<i>zntR</i>	CP	
Transcriptional regulator, ArsR family	Orange	Green	Green	Green	BTH_I10561	Rv2034	<i>arsR</i>	CP	
Alanine dehydrogenase / pyridine nucleotide transhydrogenase	Orange	Green	Green	Green	BTH_I10922	Rv2780	<i>pntA</i>	IM	
Heat shock protein, HSP20 family	Orange	Green	Green	Green	BTH_I10924	Rv0251c	<i>ibpB</i>	CP	
Universal stress protein, putative	Orange	Green	Green	Green	BTH_I11268	Rv2623	<i>uspE</i>	CP	
AMP-binding domain protein / put. acyl-coA synthase / carnitine-CoA ligase	Orange	Green	Green	Green	BTH_I11686	Rv3515c	<i>caiC</i>	CP	
Domain of unknown function / conserved hypothetical protein	Orange	Green	Green	Green	na	BTH_I11714	Rv0140	<i>na</i>	Secreted
Methylmalonate-semialdehyde dehydrogenase / phenylacetaldehyde dehydrogenase	Orange	Green	Green	Green	BTH_I11801	Rv0753c	<i>feaB</i>	CP	
Pyochelin synthetase / conserved hypothetical protein	Orange	Green	Green	Green	BTH_I11828	Rv0100	<i>entF</i>	CP/IM	
4-Aminobutyrate aminotransferase / put. lysine-(epsilon) aminotransferase	Orange	Green	Green	Green	BTH_I12119	Rv3290c	<i>puuE</i>	CP	
Proline iminopeptidase / predicted aminoacylate hydrolase	Orange	Green	Green	Green	BTH_I12193	Rv0840c	<i>rutD*</i>	CP	
2-Oxoisovalerate dehydrogenase subunit / pyruvate dehydrogenase E1	Orange	Green	Green	Green	na	BTH_I12304	Rv2497c	<i>na</i>	CP
Sulphate permease family of anion transporters	Orange	Green	Green	Green	BTH_I12316	Rv1707	<i>ychM</i>	IM	
Stress response protein / HSP20 family	Orange	Green	Green	Green	na	BTH_I12321	Rv0251c	<i>na</i>	IM

* partial

310

311 **Fig. S2. Common themes in persister cell transcriptomes.** Transcriptome312 datasets of *B. thailandensis* persisters (Bt; this study), *M. tuberculosis* persisters (TB,313 Keren *et al.* 2011), and *E. coli* persisters (Ec; Keren *et al.* 2006) were analysed for

314 similarities. Expression ratios refer to Bt persisters vs. mid-log cultures (Bt-P/ML) and

315 stationary phase cultures (Bt-P/S), respectively, TB persisters revealed with D-

316 cycloserine vs. mid-log phase cells before antibiotic challenge (TB-P), and *E. coli*

317 persisters revealed with ampicillin vs. mid-log phase cells before antibiotic challenge

318 (Ec-P). The genome of *B. thailandensis* was searched for orthologues of reported TB

319 persister genes using BLASTP and the RNAseq dataset was analysed for

320 expression ratios of these 17 homologues. Note that one TB gene, Rv1707, has two

321 orthologues in *B. thailandensis*. Next, the genome of *E. coli* strain MG1655 was

322 searched for orthologues of the common persister genes using BLASTP and a

323 published microarray dataset (Keren *et al.* 2006) was analysed for expression ratios324 in *E. coli*. A second *E. coli* dataset (Shah *et al.* 2006), which also includes a

325 comparison of persisters vs. stationary phase cells, was also analysed; none of the


326 orthologues exhibited induced expression levels. Details on the function and

327 subcellular localisation of the encoded protein were obtained from public databases.

328 Colour coding for expression ratios: orange = ratio < 0.5 ; grey = ratio 0.5 to 2; green

329 = ratio > 2 .

330



331

332 **Fig S3. Expression of the heat shock regulon in *B. thailandensis* persister**333 **cells.** Heat map of expression ratios of genes described to be part of the heat shock


334 response in stationary phase samples vs. mid-log samples (S/ML), persisters vs.

335 mid-log samples (P/ML) and persisters vs. stationary phase samples (P/S). Colour

336 coding: orange = ratio < 0.5; grey = ratio 0.5 to 2; green = ratio > 2.

337

338



339

340 **Fig S4. Contribution of multidrug efflux systems and β -lactamases.** A) Heat

341 map of expression ratios of selected multidrug efflux systems in stationary phase

342 samples vs. mid-log samples (S/ML), persisters vs. mid-log samples (P/ML) and

343 persisters vs. stationary phase samples (P/S). Colour coding: orange = ratio < 0.5;

344 grey = ratio 0.5 to 2; green = ratio >2. B-C) Remaining ceftazidime concentration

345 after 24 hrs incubation with or without bacteria determined by a well diffusion assay.

346 Zone of inhibition of ceftazidime standard at 400 μ g/ml (same as used in persister

347 assay), persister assay supernatants (with bacteria), or mock persister assay without


348 bacteria (B) and results of measurements of the diameter of the zone of inhibition in

349 the test samples relative to the 400 μ g/ml standard (C). Bars and error bars in C)

350 represent average and standard deviations of three independent samples.

351

352



353

354 **Fig. S5. (A) One dimensional solution of O_2 diffusion into water.** It was assumed

355 that the temperature of the water was 37 °C (diffusion coefficient of oxygen in water

356 at this temperature is used) and that the initial oxygen content of the water was

357 depleted to zero. The lowest line is the diffusion level after 1 hour and they progress

358 upwards at one hour intervals for each line up to 24 hrs. The vertical lines represent

359 the depth of medium in a 1.9 cm² (surface area of the base) cylindrical well plate at

360 assay volumes of 0.25 ml, 0.5 ml, 1 ml and 2 ml. **(B)** The generation of an oxygen-

361 limited bottom layer during static incubation was assessed by using different

362 volumes of a mixture of bacteria and antibiotics and enumerating survival

363 frequencies after 24 hrs incubation. The volumes correspond to a depth of 1.3 mm


364 (0.25 ml), 2.6 mm (0.5 ml), 5.25 mm (1 ml), and 10.5 mm (2 ml) of the assay mixture

365 inside the wells. In all experiments, bacteria grown to stationary phase were used

366 and challenged with antibiotics under static incubation at 37 °C. Error bars represent

367 the standard deviation over the mean from at least three independent experiments.

368




369

370

371 **Fig. S6. Two- and three-state switching models.** In all models presented, the
 372 different phenotypic population states are represented by circles and the switching
 373 rates between them by arrows. Under antibiotic treatment, a population state i
 374 declines (or grows if the drug is ineffective) at a rate k_i . **(A)** The original two-state
 375 stochastic switching model with a population of normal (n) and persister (p) cells and
 376 switching rates between them (a and b) (8). **(B)** The general three-state switching
 377 model with normal cells (n) and two distinct persister subtypes ($p1$ and $p2$). **(C)** The
 378 modified three-state model with $p1$ cells being tolerant to ceftazidime and $p2$ cells
 379 being tolerant to ciprofloxacin. Blue arrows indicate that the switching rates between
 380 the normal susceptible cells n and $p1$ (rates a and b) depend on the oxygen
 381 concentration. Red arrows indicate that the size of the ciprofloxacin-tolerant
 382 population $p2$ is independent of the oxygen level. This is incorporated into the model
 383 by setting the switching rates $f = d$ and $e = c$.

384

385



386

387


388

389 **Fig. S7. Parameter sweeps of the two-state model plotting only a and b .** In all
 390 plots, the green squares correspond to parameter sets that yield a low survivor
 391 number at 24 hrs of between 7.6×10^{-7} and 1.7×10^{-6} , which corresponds to the
 392 survivor frequencies found after ceftazidime treatment in the 0.5 ml assay volume.
 393 The blue circles correspond to parameter sets that yield a high survivor number at 24
 394 hrs and 48hrs of between 0.0238 and 0.0302 and 0.0106 and 0.037 respectively.
 395 These correspond to the survivor frequencies found after ceftazidime treatment in
 396 the 1 ml assay volume. **(A)** Initial population of $p = 0$ and $n = 1$. **(B)** Initial population
 397 of $p = 0.01$ and $n = 0.99$. **(C)** Initial population of $p = 0.05$ and $n = 0.95$. **(D)** Initial
 398 population of $p = 10^{-4}$ and $n = 1-10^{-4}$. Note that in all plots the two parameter sets are
 399 distinct and separate.

400

401

402



403


404

405 **Fig. S8. Extended parameter sweeps of the two-state model.** In both plots, each
 406 blue dot represents a distinct set of a , b and k_n parameters of the two-state model
 407 (see Fig. S4A), which predict a survival frequency between 2.4×10^{-2} and 3.0×10^{-2}
 408 after 24 hrs. This corresponds to the survival frequencies observed after 24 hrs
 409 ceftazidime treatment in 1 ml volumes (see Fig. S2B). Every green square is a
 410 distinct set of a , b and k_n parameters of the two-state model resulting in a survival
 411 frequency between 7.6×10^{-7} and 1.7×10^{-6} after 24 hrs. This corresponds to the
 412 survival frequencies observed after 24 hrs ceftazidime treatment in 0.5 ml volumes

413 (see Fig. S1B). **(A)** Parameter sweeps over ranges of a , b and k_n (assume $k_p = 0$),
414 assuming an initial population of $p = 10^{-6}$ and $n = 1-10^{-6}$. **(B)** Parameter sweeps over
415 ranges of a , b and k_n (assume $k_p = 0$), assuming an initial population of $p = 0$ and $n =$
416 1. **(C)** Solutions of the two-state model which conform to high and low survivor
417 counts observed under different assay volumes *in vitro*. For these solutions, it is
418 assumed that $k_p = 0$ and that at $t = 0$, $n = 1$ and $p = 0$. The parameter sweeps were
419 run over the parameter ranges depicted on the axes.

420

421




422

423 **Fig. S9. Deletion of *narG* in *B. pseudomallei* prevents anaerobic growth on**
 424 **nitrate and causes a significant reduction in nitrate reductase activity under**
 425 **aerobic conditions.** An in-frame nitrate reductase deletion mutant ($\Delta narG$) was
 426 created using the suicide vector pDM4 carrying the BPSL2309 knockout cassette
 427 (pD2309). **(A)** PCR confirmation of the $\Delta narG$ deletion mutant using primers binding
 428 300 bp up and downstream of the target gene (BPSL2309 - *narG*), generating a 600
 429 bp product in the mutant and a much larger band in the wild-type (over 3,500 bp), not
 430 detected under the PCR conditions used. Lane 1 – 1 kb DNA ladder; lane 2 –

431 negative control (H₂O); lane 3 – pD2309; lane 4 – wild-type *B. pseudomallei* lysate;
432 lane 5 – $\Delta narG$ colony lysate. Lack of a WT band and presence of 600 bp band for
433 $\Delta narG$ confirms the deletion of BPSL2309. **(B)** Wild-type *B. pseudomallei* (black
434 bars) and $\Delta narG$ (grey bars) were grown anaerobically in the presence or absence of
435 20 mM sodium nitrate. No anaerobic growth was seen for $\Delta narG$. Data is the
436 average of three independent biological replicates. Asterisks (**) denote statistically
437 significant difference between WT and $\Delta narG$ ($P < 0.01$). **(C)** Aerobic growth in M9
438 minimal media supplemented with 20 mM sodium succinate and 20 mM sodium
439 nitrate for wild-type (filled squares) and $\Delta narG$ (filled circles). Samples were taken
440 throughout aerobic growth to determine the level of nitrate reductase activity in both
441 *B. pseudomallei* cultures. **(D)** Relative nitrate reductase (NAR) activity was
442 measured by determining the concentration of nitrite in the media using the Griess
443 reagent system. Concentration of nitrite produced during aerobic growth was
444 measured for the wild-type (black bars) or $\Delta narG$ (grey bars). The $\Delta narG$ deletion
445 mutant could not reduce nitrate to nitrite, confirming a lack of NAR activity in this
446 mutant. **(E)** Aerobic growth of wild-type *B. pseudomallei* and $\Delta narG$ in L-broth.
447 Results presented are the mean of three biological replicates, each with two
448 technical replicates used when performing the Griess reaction. Error bars \pm
449 standard deviation (SD).

450

451



452

453 **Fig. S10. Phenotypes of different types of persister cells.** *B. thailandensis* strain
454 E264 from stationary growth phase was challenged with 100 x MIC ceftazidime or 10
455 x MIC ciprofloxacin for 24 hours. Images represent LB agar plates with colonies
456 derived from serial dilutions of washed surviving cells. The ceftazidime-derived
457 persister plate shown in left panel was incubated for 24 hours at 37 °C, whereas the
458 ciprofloxacin-derived plate shown in the right panel had been incubated for 48 hours
459 at 37 °C.

460

461

462 **Table S1. Bacterial strains used in this study.**

Strain	Description	Reference
<i>Burkholderia thailandensis</i>		
E264	Environmental isolate, sequenced strain	(19, 20)
DW503	E264 efflux pump mutant ($\Delta amrR-oprA$, Km ^S Gm ^S Sm ^S)	(21)
Phuket 4W-1	Water isolate from Thailand	(22)
CDC3015869	Clinical isolate from Texas	(23)
CDC2721121	Clinical isolate from Louisiana	(23)
<i>Burkholderia pseudomallei</i>		
K96243	Clinical isolate from Thailand, sequenced strain	(24)
K96243 $\Delta narG$	Deletion of BPSL2309 in strain K96243	This study
<i>Escherichia coli</i>		
MG1655	K-12 derivative (F ⁻ λ^- <i>ilvG^- rfb-50 rph-1</i>)	(25)

463

464

465 **Table S2. Parameter sweeps of the two-state switching model.** The ranges shown are those that either conform to the
 466 high survivor numbers at 24 hrs and 48 hrs for the ceftazidime killing under 1 ml assay volume (High cefta) or the 24 hrs
 467 low survivor numbers at 0.5 ml assay volume (Low cefta) or the ciprofloxacin kill curve (Ciprofloxacin). Parameter ranges
 468 tested: $a \in (0, 10)$, $b \in (0, 10)$, $k_n \in (-5, 0)$, $k_p \in (-0.05, 0)$.

Initial Conditions (n , p)	Tested Range Solution Ranges	Parameter ranges found to be within error ranges of high or low survivor numbers under ceftazidime treatment or to have agreed with ciprofloxacin kill curve (min, max)			
		a	b	k_n	k_p
(1 , 0)	High ceftazidime	0.002 , 0 , 0.05	0.04	-0.5 , -0.16	-0.05 , 0
	Low ceftazidime	10^{-6} , 10^{-7} , 10	10	-5 , -0.6	-0.05 , 0
	Ciprofloxacin	0.02 , 0 , 0.12	0.03	-2.2 , -1.7	-0.1 , 0
(0.99 , 0.01)	High ceftazidime	0 , 0.04	0 , 0.05	-0.5 , -0.17	-0.05 , 0

	Low	10^{-7}	, 0.04 , 10	-5 , -0.6	-0.05 , 0
	ceftazidime	10			
	Ciprofloxacin	0.01	, 0.02 , 0.1	-2.2 , -2	-0.1 , -0.02
		0.03			
(0.9999 , 10^{-4})	High	0.01	, 0 , 0.04	-5 , -0.25	-0.05 , 0
	ceftazidime	0.4			
	Low	10^{-7}	, 0.02 , 10	-5 , -0.6	-0.05 , 0
	ceftazidime	10			
	Ciprofloxacin	None	None	None	None
(0.95 , 0.05)	High	0 , 0.02	0 , 0.05	-0.5 , -0.21	-0.05 , 0
	ceftazidime				
	Low	10^{-7}	, 0.4, 10	-5 , -0.6	-0.05 , 0
	ceftazidime	10			
	Ciprofloxacin	None	None	None	None

470 **Additional References**

- 471 1. **Hamad MA, Austin CR, Stewart AL, Higgins M, Vazquez-Torres A, Voskuil**
472 **MI.** 2011. Adaptation and antibiotic tolerance of anaerobic *Burkholderia*
473 *pseudomallei*. Antimicrob. Agents. Chemother. **55**:3313-3323.
- 474 2. **Andreae CA, Titball RW, Butler CS.** 2014. Influence of the molybdenum
475 cofactor biosynthesis on anaerobic respiration, biofilm formation and motility in
476 *Burkholderia thailandensis*. Res. Microbiol. **165**:41-49.
- 477 3. **Arena ME, Saguir FM, Manca de Nadra MC.** 1999. Arginine, citrulline and
478 ornithine metabolism by lactic acid bacteria from wine. Int. J. Food Microbiol.
479 **52**:155-161.
- 480 4. **Casiano-Colon A, Marquis RE.** 1988. Role of the arginine deiminase system in
481 protecting oral bacteria and an enzymatic basis for acid tolerance. Appl. Environ.
482 Microbiol. **54**:1318-1324.
- 483 5. **Chantratita N, Tandhavanant S, Wikraiphat C, Trunck LA, Rhoil DA,**
484 **Thanwisai A, Saiprom N, Limmathurotsakul D, Korbsrisate S, Day NP,**
485 **Schweizer HP, Peacock SJ.** 2012. Proteomic analysis of colony morphology
486 variants of *Burkholderia pseudomallei* defines a role for the arginine deiminase
487 system in bacterial survival. J. Proteomics **75**:1031-1042.
- 488 6. **Keren I, Minami S, Rubin E, Lewis K.** 2011. Characterization and transcriptome
489 analysis of *Mycobacterium tuberculosis* persisters. mBio **2**.
- 490 7. **Keren I, Shah D, Spoering A, Kaldalu N, Lewis K.** 2004. Specialized persister
491 cells and the mechanism of multidrug tolerance in *Escherichia coli*. J. Bacteriol.
492 **186**:8172-8180.

- 493 8. **Shah D, Zhang Z, Khodursky A, Kaldalu N, Kurg K, Lewis K.** 2006.
494 Persisters: a distinct physiological state of *E. coli*. *BMC Microbiol.* **6**:53.
- 495 9. **Målen H, Berven FS, Fladmark KE, Wiker HG.** 2007. Comprehensive analysis
496 of exported proteins from *Mycobacterium tuberculosis* H37Rv. *Proteomics*
497 **7**:1702-1718.
- 498 10. **Hu Y, Movahedzadeh F, Stoker NG, Coates ARM.** 2006. Deletion of the
499 *Mycobacterium tuberculosis* α -crystallin-Like *hspX* gene causes increased
500 bacterial growth *in vivo*. *Infect. Immun.* **74**:861-868.
- 501 11. **Guisbert E, Yura T, Rhodius VA, Gross CA.** 2008. Convergence of molecular,
502 modeling, and systems approaches for an understanding of the *Escherichia coli*
503 heat shock response. *Microbiol. Mol. Biol. Rev.* **72**:545-554.
- 504 12. **Kiran M, Chauhan A, Dziedzic R, Maloney E, Mukherji SK, Madiraju M,**
505 **Rajagopalan M.** 2009. *Mycobacterium tuberculosis* *ftsH* expression in response
506 to stress and viability. *Tuberculosis* **89**:S70-S73.
- 507 13. **Fischer B, Rummel G, Aldridge P, Jenal U.** 2002. The FtsH protease is
508 involved in development, stress response and heat shock control in *Caulobacter*
509 *crenscentus*. *Mol. Microbiol.* **44**:461-478.
- 510 14. **Rholl DA, Papp-Wallace KM, Tomaras AP, Vasil ML, Bonomo RA, Schweizer**
511 **HP.** 2011. Molecular investigations of PenA-mediated beta-lactam resistance in
512 *Burkholderia pseudomallei*. *Front. Microbiol.* **2**.
- 513 15. **Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S.** 2004. Bacterial
514 persistence as a phenotypic switch. *Science* **305**:1622-1625.

- 515 16. **Richardson DJ.** 2000. Bacterial respiration: a flexible process for a changing
516 environment. *Microbiology* **146**:551-571.
- 517 17. **Gonzalez PJ, Correia C, Moura I, Brondino CD, Moura JJ.** 2006. Bacterial
518 nitrate reductases: Molecular and biological aspects of nitrate reduction. *J. Inorg.*
519 *Biochem.* **100**:1015-1023.
- 520 18. **Tashiro Y, Kawata K, Taniuchi A, Kakinuma K, May T, Okabe S.** 2012. RelE-
521 mediated dormancy is enhanced at high cell density in *Escherichia coli*. *J.*
522 *Bacteriol.* **194**:1169-1176.
- 523 19. **Brett P, Deshazer D, Woods D.** 1998. *Burkholderia thailandensis* sp. nov., a
524 *Burkholderia pseudomallei*-like species. *Int. J. Syst. Bacteriol.* **48**:317-320.
- 525 20. **Yu Y, Kim HS, Chua HH, Lin CH, Sim SH, Lin D, Derr A, Engels R, DeShazer**
526 **D, Birren B, Nierman WC, Tan P.** 2006. Genomic patterns of pathogen
527 evolution revealed by comparison of *Burkholderia pseudomallei*, the causative
528 agent of melioidosis, to avirulent *Burkholderia thailandensis*. *BMC Microbiol.*
529 **6**:46.
- 530 21. **Burnick M, Bolton A, Brett P, Watanabe D, Woods D.** 2001. Identification of
531 the acid phosphatase (*acpA*) gene homologues in pathogenic and non-
532 pathogenic *Burkholderia* spp. facilitates *TnPhoA* mutagenesis. *Microbiology*
533 **147**:111-120.
- 534 22. **Finkelstein RA, Atthasampunna P, Chulasamaya M.** 2000. *Pseudomonas*
535 (*Burkholderia*) *pseudomallei* in Thailand, 1964–1967: geographic distribution of
536 the organism, attempts to identify cases of active infection, and presence of
537 antibody in representative sera. *Am. J. Trop. Med. Hyg.* **62**:232-239.

- 538 23. **Glass MB, Gee JE, Steigerwalt AG, Cavuoti D, Barton T, Hardy RD, Godoy**
539 **D, Spratt BG, Clark TA, Wilkins PP.** 2006. Pneumonia and septicemia caused
540 by *Burkholderia thailandensis* in the United States. *J. Clin. Microbiol.* **44**:4601-
541 4604.
- 542 24. **Holden MTG, Titball RW, Peacock SJ, Cerdeno-Tarraga AM, Atkins T,**
543 **Crossman LC, Pitt T, Churcher C, Mungall K, Bentley SD, Sebahia M,**
544 **Thomson NR, Bason N, Beacham IR, Brooks K, Brown KA, Brown NF,**
545 **Challis GL, Cherevach I, Chillingworth T, Cronin A, Crossett B, Davis P,**
546 **DeShazer D, Feltwell T, Fraser A, Hance Z, Hauser H, Holroyd S, Jagels K,**
547 **Keith KE, Maddison M, Moule S, Price C, Quail MA, Rabinowitsch E,**
548 **Rutherford K, Sanders M, Simmonds M, Songsivilai S, Stevens K, Tumapa**
549 **S, Vesaratchavest M, Whitehead S, Yeats C, Barrell BG, Oyston PCF,**
550 **Parkhill J.** 2004. Genomic plasticity of the causative agent of melioidosis,
551 *Burkholderia pseudomallei*. *Proc. Natl. Acad. Sci. U.S.A.* **101**:14240-14245.
- 552 25. **Guyer MS, Reed RR, Steitz JA, Low KB.** 1981. Identification of a sex-factor-
553 affinity site in *E. coli* as gamma delta. *Cold Spring Harb Symp Quant Biol* **45 Pt**
554 **1**:135-140.

555

556